... DDCs dermal dendritic cells 真皮内树突状细胞 DFS disease free survival 无瘤生存 DMF dose modifying factor 剂量修饰因子 ...
基于16个网页-相关网页
无瘤生存期 disease-free survival ; disease-free interval ; DFI ; DFS
无瘤生存率 disease-free survival ; recurrence free survival rate
持续无瘤生存期 continuous disease-free survival time
的无瘤生存期 disease-free interval ; DFI
无瘤生存时间 Disease-free Survival ; DFS
延长持续无瘤生存期 continuous disease-free survival time ; CDFS
提高患者的无瘤生存率 disease-free survival ; DFS
及无瘤生存率 EFS ; eventfree survival
患者的无瘤生存率 DFS ; disease-free survival
Overall survival, tumor-free survival, re-currence and metastases rate without significant between thetwo group.
比较两组的总生存率、无瘤生存率、复发率及转移率无明显差异。
参考来源 - AFP阴性肝细胞肝癌的外科疗效和预后因素分析Results Four-year overall survival rates were 58%;recurrence-free survival rates were 49%.
结果515例肝癌患者的4年总生存率为58%,无瘤生存率为49%。
参考来源 - 早期肝癌复发与生存预测标记物的评价·2,447,543篇论文数据，部分数据来源于NoteExpress
影响无瘤生存期的因素为：BVI、TNM分期和N分期。
The factors influencing disease-free survival are BVI, TNM and LNM.
无瘤生存的每一天对于肝癌患者来说其重要性在夸大都不过分。
It's hard to overstate the importance to the patient's quality of life of each day that they remain free of liver cancer.
目的：探讨30岁以下乳腺癌的临床特点、无瘤生存率和影响预后的因素。
Objective: To explore the clinical characteristics, survival and prognosis of breast cancer patients under 30 years.
应用推荐